OmniAb (OABI) Projected to Post Earnings on Wednesday

OmniAb (NASDAQ:OABI) is expected to be releasing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $9.0030 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $1.72 on Monday. OmniAb has a fifty-two week low of $1.22 and a fifty-two week high of $3.53. The company has a market cap of $247.61 million, a price-to-earnings ratio of -2.97 and a beta of 0.13. The business’s 50 day moving average price is $1.84 and its 200-day moving average price is $1.75.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a research note on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $6.67.

Insider Transactions at OmniAb

In other OmniAb news, CFO Kurt A. Gustafson sold 23,922 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $1.96, for a total transaction of $46,887.12. Following the completion of the sale, the chief financial officer directly owned 252,688 shares of the company’s stock, valued at approximately $495,268.48. This represents a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew W. Foehr sold 30,843 shares of OmniAb stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.71, for a total transaction of $52,741.53. Following the completion of the transaction, the chief executive officer directly owned 4,403,277 shares in the company, valued at approximately $7,529,603.67. The trade was a 0.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 130,021 shares of company stock valued at $233,398 over the last quarter. 8.60% of the stock is currently owned by corporate insiders.

Institutional Trading of OmniAb

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Woodline Partners LP acquired a new stake in shares of OmniAb in the 3rd quarter worth $4,571,000. Kent Lake PR LLC raised its stake in OmniAb by 677.8% in the second quarter. Kent Lake PR LLC now owns 1,750,000 shares of the company’s stock valued at $3,045,000 after buying an additional 1,525,000 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in OmniAb by 234.4% in the third quarter. ADAR1 Capital Management LLC now owns 1,090,628 shares of the company’s stock worth $1,745,000 after acquiring an additional 764,520 shares in the last quarter. Cadian Capital Management LP grew its stake in shares of OmniAb by 20.7% during the fourth quarter. Cadian Capital Management LP now owns 4,434,954 shares of the company’s stock worth $8,205,000 after acquiring an additional 759,386 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of OmniAb by 17.0% during the fourth quarter. Geode Capital Management LLC now owns 2,722,692 shares of the company’s stock valued at $5,038,000 after acquiring an additional 396,456 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.